Trials / Completed
CompletedNCT05965089
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
A First-in-human, Randomised Double-blind, Placebo-controlled 2-part Study to Evaluate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single Ascending Doses of AX-202 in Healthy Subjects and Multiple Ascending Doses of AX-202 in Patients With Mild to Moderate Chronic Plaque Psoriasis.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Arxx Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of AX-202 infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo | Placebo |
| BIOLOGICAL | AX-202 | Humanized monoclonal antibody |
Timeline
- Start date
- 2023-04-25
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2023-07-28
- Last updated
- 2024-12-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05965089. Inclusion in this directory is not an endorsement.